Olaparib shows promise for Early-Stage prostate cancer recurrence
NCT ID NCT03047135
First seen May 13, 2026 · Last updated May 13, 2026
Summary
This study tests the drug olaparib in 51 men whose prostate cancer has returned after surgery and is at high risk of spreading. Olaparib works by blocking a repair process in cancer cells, and early studies suggest it may be more effective when given earlier in the disease. The main goal is to see if olaparib can lower PSA levels by at least 50%.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allegheny Cancer Center
Pittsburgh, Pennsylvania, 15212, United States
-
Johns Hopkins Hospital
Baltimore, Maryland, 21231, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
Conditions
Explore the condition pages connected to this study.